Form 4: Core Scientific Officer Sells Shares Under 10b5-1 Plan

Core Scientific, Inc. officer Todd Duchene sold 10,000 shares of common stock for approximately $1.65 million under a pre-arranged trading plan.

Summary

• Todd Duchene, Chief Legal and Administrative Officer of Core Scientific, Inc., reported a transaction involving the sale of 10,000 shares of common stock.
• The sale occurred on April 6, 2026, and was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025.
• The shares were sold at a weighted average price of $16.4865, with individual transaction prices ranging from $16.285 to $16.78.
• Following this transaction, Duchene beneficially owns 2,037,089 shares of common stock directly.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a slightly negative sentiment due to the sale of shares by a key executive, despite being executed under a pre-planned trading strategy.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market.
• The sale represents a disposal of company stock by an insider, potentially signaling a lack of confidence or a need for personal liquidity.

Risks

• The Rule 10b5-1 plan indicates a pre-determined strategy for stock sales, which mitigates insider trading concerns but still represents a reduction in insider holdings.
• Future sales under the plan could continue to put downward pressure on the stock price if executed in large volumes.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on a past transaction.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.285 to $16.78, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, can sometimes be interpreted by the market as a bearish signal, regardless of the underlying strategic reasons. For Core Scientific, a company in the highly volatile digital asset mining sector, such transactions by key executives warrant close observation by investors.

Stakeholder Impact

• Shareholders may view the sale by an executive as a negative signal, potentially impacting stock price.
• The Rule 10b5-1 plan structure is designed to provide a defense against insider trading allegations, which is a positive governance aspect.

Next Steps

• The Reporting Person may continue to sell shares under the Rule 10b5-1 plan as previously established.
• The company may receive requests for detailed transaction information from the SEC or security holders.

Key Dates

Recommendation

The filing reports an insider sale under a 10b5-1 plan, which is a routine event and does not provide sufficient information to warrant a strong buy or sell recommendation. The sale was executed at a price range that is not significantly outside the current market, and the executive retains a substantial number of shares. Investors should monitor future filings and company performance for more definitive signals.

Keywords

Core Scientific, CORZ, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Todd Duchene, Beneficial Ownership, Securities Exchange Act